Medical aesthetics has evolved from niche luxury to mainstream consumer category, and valuation multiples have expanded accordingly. PE firms, regional health systems, and established beauty/wellness platforms are all acquiring med spas, driving competition for quality assets. Understanding your spa's value requires translating client loyalty and revenue predictability into EBITDA metrics that buyers actually price.

Start with EBITDA. Med spa EBITDA calculation is deceptively simple but often mishandled. Revenue minus cost of goods (injectable supplies, skincare products, laser consumables), minus direct labor (injectors, estheticians, front desk), minus facility costs (rent, utilities, insurance) gives gross EBITDA. Owner salary compensation depends on role: if you're actively injecting or managing operations, benchmark your salary to market (typically $100-180K for an experienced injector-owner in major metros, lower in secondary markets). Only add back salary above this market rate.

Once you have clean EBITDA, multiples range from 5x-10x. Premium multiples (8x-10x) require recurring revenue (60%+ of gross), compliant medical director oversight, multiple providers, and strong brand. Transactional spas with owner-only operations and 30-40% recurring revenue trade at 5x-6x. Understanding which category your spa falls into is critical.

Recurring revenue is the valuation lever. Most first-time med spa owners think in transactional buckets: a filler treatment = $400 revenue, one-time. But recurring revenue—membership programs, injectable retainers, skincare subscriptions—transforms buyer confidence dramatically. A client on a $200/month injectable membership (4 touch-ups per year) represents $2,400 annual revenue with minimal acquisition cost. That recurring relationship is worth 3-4x more to a buyer than a one-time procedure. Calculate your own recurring revenue percentage: memberships, skincare subscriptions, and clients with documented repeat injection appointments (2+ treatments per year within treatment protocol) count as recurring.

Spas hitting 60%+ recurring revenue consistently trade at 8x-10x EBITDA. Those at 40-50% trade at 6x-7x. Those below 30% trade at 5x or lower because buyer cash flow projections are too uncertain. If your recurring revenue is below 50%, the single highest-impact initiative is launching or optimizing membership programs. This typically takes 6-12 months to embed and can add $300K-$600K to enterprise value through multiple expansion alone.

Client database quality is undervalued by most spa owners. A comprehensive digital database (customer names, phone, email, treatment history, last visit, LTV) is intellectual property buyers specifically value. It enables email marketing, churn prediction, and customer reactivation campaigns that PE firms execute post-acquisition. Document your active client count (seen in past 90 days) and average customer lifetime value. Spas with 5,000+ active clients at $1,500+ LTV per client are acquisition-grade assets; smaller databases or fragmented records create buyer friction.

Medical director structure is compliance non-negotiable. Buyers conduct legal due diligence on prescribing practices, treatment protocols, and physician supervision. If you're the only provider and owner, succession risk is priced as -0.5 to -1.5x EBITDA multiple discount. If you have a separate, compliant medical director (employed, regularly present, with documented protocols), that eliminates buyer compliance concerns and supports premium pricing. Medical directors typically cost $50-100K annually but can add $250K-$500K+ in enterprise value through multiple expansion and buyer confidence.

Provider team depth matters enormously. Owner-only spas are operationally limited and transaction-dependent. Spas with 2-3+ licensed injectors or providers (RNs, NPs, PAs with injectable credentials) command 0.5-1x EBITDA premium because buyer post-acquisition scaling is straightforward. Document each provider: credentials, tenure, client retention, revenue attribution, and compensation. Providers with strong individual client bases (500+) and 3+ year tenure are valued as retained assets; high-turnover providers are liabilities.

Service mix diversification reduces revenue concentration risk. Injectables (Botox, fillers) are 40-50% of revenue and recur naturally every 8-12 weeks. Devices (laser, IPL, RF microneedling) are 25-35% and command higher up-front tickets. Skincare retail and professional services are 15-25% and highly repeatable. Spas with all three lines are more resilient; those dependent on a single service (e.g., injectables only) face buyer risk if market shifts or competition emerges.

Brand and reputation reduce buyer acquisition costs. Spas with 4.7+ Google ratings, 1,000+ reviews, and 30-40% new client referral rates demonstrate market authority and pricing power. Document review scores, referral percentages, and social media engagement. Strong local positioning ("the med spa for injectables in [neighborhood]" or "voted best med spa 3 years running") supports retention and justifies premium pricing to buyers.

Work with a healthcare-specialized M&A advisor 12-18 months before intended sale. They'll quantify your recurring revenue gap, identify provider retention risks, and build a pre-sale optimization plan. Common moves: launching membership programs, adding a second provider, or hiring a separate medical director. These moves cost $30-80K but add $300K-$700K+ in enterprise value.